[{"id":"2abe584e-efd0-467e-a3cd-03637a2183a6","acronym":"","url":"https://clinicaltrials.gov/study/NCT01903330","created_at":"2021-01-18T08:34:13.635Z","updated_at":"2024-07-02T16:36:10.432Z","phase":"Phase 2","brief_title":"ERC1671/GM-CSF/Cyclophosphamide for the Treatment of Glioblastoma Multiforme","source_id_and_acronym":"NCT01903330","lead_sponsor":"Epitopoietic Research Corporation","biomarkers":" IL6 • IL2RA • CD4 • IL10 • CSF2","pipe":"","alterations":" ","tags":["IL6 • IL2RA • CD4 • IL10 • CSF2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Avastin (bevacizumab) • cyclophosphamide • Mvasi (bevacizumab-awwb) • Zirabev (bevacizumab-bvzr) • Sitoiganap (ERC1671) • Leukine (sargramostim) • cyclophosphamide intravenous"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 84","initiation":"Initiation: 03/01/2014","start_date":" 03/01/2014","primary_txt":" Primary completion: 03/01/2023","primary_completion_date":" 03/01/2023","study_txt":" Completion: 03/01/2023","study_completion_date":" 03/01/2023","last_update_posted":"2022-05-16"},{"id":"9659d6c1-cda3-4e44-851f-94251b487a0b","acronym":"","url":"https://clinicaltrials.gov/study/NCT05366062","created_at":"2022-05-09T11:56:24.382Z","updated_at":"2024-07-02T16:36:10.460Z","phase":"Phase 2","brief_title":"ERC1671 to Treat Malignant Gliomas When Given in Combination With GM-CSF, Cyclophosphamide, Bevacizumab and Pembrolizumab","source_id_and_acronym":"NCT05366062","lead_sponsor":"Epitopoietic Research Corporation","biomarkers":" CD4","pipe":"","alterations":" ","tags":["CD4"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab) • Avastin (bevacizumab) • temozolomide • cyclophosphamide • Sitoiganap (ERC1671)"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 28","initiation":"Initiation: 07/01/2022","start_date":" 07/01/2022","primary_txt":" Primary completion: 07/31/2025","primary_completion_date":" 07/31/2025","study_txt":" Completion: 07/31/2026","study_completion_date":" 07/31/2026","last_update_posted":"2022-05-13"}]